Compare RYN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | ERAS |
|---|---|---|
| Founded | 1926 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.5B |
| IPO Year | 1994 | 2021 |
| Metric | RYN | ERAS |
|---|---|---|
| Price | $21.00 | $18.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $26.00 | $12.08 |
| AVG Volume (30 Days) | 2.1M | ★ 5.1M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.96% | N/A |
| EPS Growth | 26.78 | ★ 36.23 |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $484,485,000.00 | N/A |
| Revenue This Year | $214.97 | N/A |
| Revenue Next Year | $10.35 | N/A |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.49 | $1.06 |
| 52 Week High | $27.34 | $19.44 |
| Indicator | RYN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 65.46 |
| Support Level | $19.49 | $1.72 |
| Resistance Level | $22.37 | $18.20 |
| Average True Range (ATR) | 0.42 | 1.30 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 58.84 | 76.31 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.